Loading...
•
Dec 31, 2024
Aurinia Q4 2024 Earnings Report
Aurinia reported a net income of $1.4 million and total revenue of $59.9 million, marking a 33% increase in revenue compared to the same period last year.
Key Takeaways
Aurinia Pharmaceuticals reported strong financial results for Q4 2024, with a significant increase in total revenue and a return to net income profitability. The company's key product, LUPKYNIS, drove sales growth, and the company is progressing with its pipeline development.
Total revenue for Q4 2024 was $59.9 million, a 33% increase year-over-year.
Net product sales of LUPKYNIS were $57.6 million, a 36% increase year-over-year.
Net income for Q4 2024 was $1.4 million, compared to a loss of $26.9 million in the same period of 2023.
Cash flow provided by operating activities was $30.1 million, a 110% increase year-over-year.
Revenue by Segment
Forward Guidance
Aurinia expects continued growth in 2025, with total revenue projected to be in the range of $250 million to $260 million and net product sales in the range of $240 million to $250 million.
Positive Outlook
- Expected total revenue in the range of $250 million to $260 million for 2025.
- Net product sales projected in the range of $240 million to $250 million for 2025.
- Focus on increasing LUPKYNIS adoption.
- Advancing AUR200 pipeline product.
- Initial results from Phase 1 study of AUR200 expected in Q2 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...